The abstract on fluctuating baseline levels of HCV is potentially a market-moving finding if it turns out that the criteria for shortening Harvoni treatment to 8 weeks in the FDA label can’t be reliably applied in practice.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.